Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.80
AGEN's Cash to Debt is ranked lower than
72% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. AGEN: 1.80 )
Ranked among companies with meaningful Cash to Debt only.
AGEN' s Cash to Debt Range Over the Past 10 Years
Min: 0.24  Med: 1.75 Max: N/A
Current: 1.8
Equity to Asset 0.32
AGEN's Equity to Asset is ranked lower than
82% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AGEN: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
AGEN' s Equity to Asset Range Over the Past 10 Years
Min: -1.33  Med: -0.02 Max: 0.92
Current: 0.32
-1.33
0.92
F-Score: 4
Z-Score: -3.81
M-Score: -2.21
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -424.97
AGEN's Operating margin (%) is ranked lower than
70% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. AGEN: -424.97 )
Ranked among companies with meaningful Operating margin (%) only.
AGEN' s Operating margin (%) Range Over the Past 10 Years
Min: -11732.38  Med: -756.46 Max: -42.23
Current: -424.97
-11732.38
-42.23
Net-margin (%) -522.70
AGEN's Net-margin (%) is ranked lower than
72% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. AGEN: -522.70 )
Ranked among companies with meaningful Net-margin (%) only.
AGEN' s Net-margin (%) Range Over the Past 10 Years
Min: -11762.54  Med: -876.95 Max: -70.95
Current: -522.7
-11762.54
-70.95
ROE (%) -174.37
AGEN's ROE (%) is ranked lower than
90% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. AGEN: -174.37 )
Ranked among companies with meaningful ROE (%) only.
AGEN' s ROE (%) Range Over the Past 10 Years
Min: -726.2  Med: -460.59 Max: -108.27
Current: -174.37
-726.2
-108.27
ROA (%) -69.96
AGEN's ROA (%) is ranked lower than
79% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. AGEN: -69.96 )
Ranked among companies with meaningful ROA (%) only.
AGEN' s ROA (%) Range Over the Past 10 Years
Min: -94.08  Med: -61.63 Max: -46.32
Current: -69.96
-94.08
-46.32
ROC (Joel Greenblatt) (%) -1219.68
AGEN's ROC (Joel Greenblatt) (%) is ranked lower than
63% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. AGEN: -1219.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1025.9  Med: -280.29 Max: -195.97
Current: -1219.68
-1025.9
-195.97
Revenue Growth (3Y)(%) -5.00
AGEN's Revenue Growth (3Y)(%) is ranked lower than
58% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. AGEN: -5.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AGEN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -54.7  Med: -5.00 Max: 100
Current: -5
-54.7
100
EBITDA Growth (3Y)(%) -7.70
AGEN's EBITDA Growth (3Y)(%) is ranked lower than
57% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. AGEN: -7.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AGEN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -51  Med: -17.20 Max: 17
Current: -7.7
-51
17
EPS Growth (3Y)(%) -16.10
AGEN's EPS Growth (3Y)(%) is ranked lower than
64% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. AGEN: -16.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AGEN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -39.9  Med: -16.10 Max: 19.4
Current: -16.1
-39.9
19.4
» AGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

AGEN Guru Trades in Q1 2015

Paul Tudor Jones 29,718 sh (+91.77%)
Robert Bruce 233,515 sh (unchged)
» More
Q2 2015

AGEN Guru Trades in Q2 2015

Jim Simons 167,015 sh (New)
Paul Tudor Jones 33,684 sh (+13.35%)
Robert Bruce 233,515 sh (unchged)
» More
Q3 2015

AGEN Guru Trades in Q3 2015

Ken Fisher 91,632 sh (New)
Steven Cohen 3,063,817 sh (New)
Jim Simons 426,443 sh (+155.33%)
Paul Tudor Jones 42,827 sh (+27.14%)
Robert Bruce 233,515 sh (unchged)
» More
Q4 2015

AGEN Guru Trades in Q4 2015

Ken Fisher 91,632 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.11
AGEN's P/B is ranked lower than
55% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.49 vs. AGEN: 3.11 )
Ranked among companies with meaningful P/B only.
AGEN' s P/B Range Over the Past 10 Years
Min: 2.5  Med: 5.12 Max: 37.35
Current: 3.11
2.5
37.35
P/S 10.79
AGEN's P/S is ranked lower than
55% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. AGEN: 10.79 )
Ranked among companies with meaningful P/S only.
AGEN' s P/S Range Over the Past 10 Years
Min: 4.61  Med: 28.42 Max: 593
Current: 10.79
4.61
593
Current Ratio 7.39
AGEN's Current Ratio is ranked higher than
66% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. AGEN: 7.39 )
Ranked among companies with meaningful Current Ratio only.
AGEN' s Current Ratio Range Over the Past 10 Years
Min: 0.64  Med: 4.77 Max: 42.49
Current: 7.39
0.64
42.49
Quick Ratio 7.38
AGEN's Quick Ratio is ranked higher than
67% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. AGEN: 7.38 )
Ranked among companies with meaningful Quick Ratio only.
AGEN' s Quick Ratio Range Over the Past 10 Years
Min: 0.64  Med: 4.73 Max: 42.49
Current: 7.38
0.64
42.49
Days Sales Outstanding 142.37
AGEN's Days Sales Outstanding is ranked lower than
84% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. AGEN: 142.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
AGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.12  Med: 16.80 Max: 96
Current: 142.37
0.12
96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.98
AGEN's Price/Net Cash is ranked lower than
56% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 5.81 vs. AGEN: 6.98 )
Ranked among companies with meaningful Price/Net Cash only.
AGEN' s Price/Net Cash Range Over the Past 10 Years
Min: 3.44  Med: 6.75 Max: 46.46
Current: 6.98
3.44
46.46
Price/Net Current Asset Value 5.47
AGEN's Price/Net Current Asset Value is ranked lower than
52% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 5.14 vs. AGEN: 5.47 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AGEN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.28  Med: 6.32 Max: 25.65
Current: 5.47
3.28
25.65
Price/Tangible Book 4.50
AGEN's Price/Tangible Book is ranked lower than
55% of the 1056 Companies
in the Global Biotechnology industry.

( Industry Median: 3.93 vs. AGEN: 4.50 )
Ranked among companies with meaningful Price/Tangible Book only.
AGEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.28  Med: 4.54 Max: 17.1
Current: 4.5
2.28
17.1
Price/Median PS Value 0.39
AGEN's Price/Median PS Value is ranked higher than
82% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: 0.89 vs. AGEN: 0.39 )
Ranked among companies with meaningful Price/Median PS Value only.
AGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 1.21 Max: 119.37
Current: 0.39
0.2
119.37
Earnings Yield (Greenblatt) (%) -52.36
AGEN's Earnings Yield (Greenblatt) (%) is ranked lower than
86% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. AGEN: -52.36 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -53.8  Med: 0.00 Max: 0
Current: -52.36
-53.8
0

More Statistics

Revenue(Mil) $19
EPS $ -1.38
Beta0.91
Short Percentage of Float15.78%
52-Week Range $2.74 - 10.16
Shares Outstanding(Mil)84.65

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 24 19 23 34
EPS($) -0.77 -0.82 -0.94 -0.74
EPS without NRI($) -0.77 -0.82 -0.94 -0.74

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AJ81.Germany,
Agenus Inc formerly known as Antigenics Inc was incorporated in 1994. The Company, along with its subsidiaries, is a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators, heat shock protein vaccines and adjuvants. It is focused on immunotherapeutic products based on core platform technologies with multiple product candidates advancing through the clinic, including several product candidates that have advanced into late-stage clinical trials through corporate partners. Its core technology portfolio consists of Heat Shock Protein Platform, and Saponin Platform. Within HSP Platform the Company is developing its Prophage Series cancer vaccines and Recombinant Series. In Prophage Series the Company has tested product candidates in Phase 3 clinical trials for the treatment of renal cell carcinoma, the common type of kidney cancer, and for metastatic melanoma, as well as in Phase 1 and Phase 2 clinical trials. In addition, the Cancer Therapy Evaluation Program of the National Cancer Institute opened patient enrollment in 2013 for a 222-patient, multi-center, randomized Phase 2 trial of Prophage Series vaccine G-200 in combination with Avastin in patients with surgically resectable recurrent glioma. HerpV, a therapeutic vaccine candidate from the Recombinant Series which contains QS-21 Stimulon, has been tested in a Phase 1 clinical trial for the treatment of genital herpes and is now in a Phase 2 trial. Within its Saponin Platform is QS-21 Stimulon adjuvant, or QS-21 Stimulon, which is used by licensees in numerous vaccines under development in trials, some as advanced as Phase 3, for a variety of diseases, including cancer, shingles, malaria, Alzheimer's disease, human immunodeficiency virus, and tuberculosis. The Company's business activities include product research and development, intellectual property prosecution, manufacturing, regulatory and clinical affairs, corporate finance and development activities, and support of its collaborations. The Company faces intense competition from pharmaceutical companies and specialized biotechnology companies that market products or that are engaged in the development of product candidates directed at cancer, infectious diseases and degenerative disorders. Several of these companies have products that utilize similar technologies and patient-specific medicine techniques. The Company is also subject to regulation under the Occupational Safety and Health Act, the Toxic Substances Control Act and the Resource Conservation and Recovery Act, and other current and potential future federal, state, or local regulations.
» More Articles for AGEN

Headlines

Articles On GuruFocus.com
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Agenus Inc.: Ingeniously Designed Vaccines To Galvanized Tomorrow's Medicine Jul 25 2014 
5 Speculative Biotech Stocks to Consider Buying Now Jan 24 2012 
Weekly CEO Buys Highlight: CTAS, VRX, TAT, AGEN, MRK Aug 20 2011 
Chairman & CEO of Agenus Inc. (AGEN) Garo Armen Buys 2,150,976 Shares Aug 18 2011 
Antigenics Inc. Reports Operating Results (10-K) Mar 16 2011 
Antigenics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,500 Shares Oct 28 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 2,000 Shares Sep 14 2010 
Antigenics Inc. (AGEN) CFO Shalini Sharp sells 1,520 Shares Jul 28 2010 

More From Other Websites
Agenus (AGEN) Catches Eye: Stock Adds 8.8% in Session Jan 22 2016
Agenus (AGEN) Stock Surges After FDA Approves Investigational New Drug Application Jan 21 2016
4 Nasdaq Stocks That Are Trading Higher Today Jan 21 2016
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 21 2016
Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and... Jan 21 2016
Agenus Announces Clearance of Investigational New Drug Applications by the FDA for anti-CTLA-4 and... Jan 21 2016
Agenus Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 14 2016
Agenus Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Jan 14 2016
Biotechnology Equity Movers and Shakers -- Agenus, Xenoport, Akebia Therapeutics, and Northwest... Jan 11 2016
AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 04 2016
Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition Jan 04 2016
Agenus Completes XOMA Antibody Manufacturing Pilot Plant Acquisition Jan 04 2016
Agenus Acquires PhosImmune, Adds Cancer Neoantigens Dec 28 2015
Technical Coverage on Biotechnology Stocks - Agenus, Progenics Pharma, Arrowhead Research, and... Dec 28 2015
Traders Look to Upside - New Reports on Agenus, Beneficial Bancorp, Healthways, and Computer Task... Dec 28 2015
Agenus, Inc. breached its 50 day moving average in a Bullish Manner : December 25, 2015 Dec 25 2015
Agenus Acquires PhosImmune with a Novel Class of Cancer Neoantigens Dec 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK